Troy Randle, DO
Cardiovascular Disease · Cherry Hill, NJNPI 1710187513
Payments from drug & device makers
Across 867 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$24K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Atricure, Inc.$1K
- Irhythm Technologies, Inc.$1K
- Novartis$1K
- plus $8K from 26 others
What the payments were for
- Speaking & faculty fees$19,06350%
- Travel & lodging$1,0253%
- Food & beverage$18,26248%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 63 | $23,791 |
| Abbott | 42 | $1,558 |
| E.r. Squibb & Sons, L.L.C. | 163 | $1,553 |
| Atricure, Inc. | 16 | $1,230 |
| Irhythm Technologies, Inc. | 37 | $1,157 |
| Novartis | 164 | $1,120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $1,080 |
| Medtronic(2 entities) | 11 | $880 |
| Impulse Dynamics (USA) Inc. | 18 | $777 |
| Amgen | 52 | $775 |
| Boehringer Ingelheim | 60 | $648 |
| AstraZeneca | 22 | $608 |
| Pfizer | 56 | $585 |
| Johnson & Johnson | 41 | $532 |
| Merck | 28 | $387 |
| Lexicon Pharmaceuticals, Inc. | 8 | $228 |
| Novo Nordisk | 9 | $218 |
| Abiomed | 3 | $203 |
| W. L. Gore & Associates, Inc. | 7 | $201 |
| American Regent | 5 | $193 |
| Kestra Medical Technology Services, Inc. | 4 | $142 |
| Getinge USA Sales, LLC | 2 | $98 |
| Bayer | 4 | $77 |
| Esperion Therapeutics, Inc. | 6 | $74 |
| Regeneron Healthcare Solutions, Inc. | 4 | $56 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Preventice Services, LLC | 1 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Heartflow, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$8,904
- Watchman$6,682
- GENERAL VASCULAR ACCESS$6,000
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$700
- OPTIMIZER$559
- Resolute$398
- CAMZYOS$342
- ZIO XT Patch$299
- GENERAL - THERAPIES$283
- WATCHMAN FLX$259
- FARXIGA$248
- Repatha$245
- LifeVest$241
- ZIO Patch$231
- Biocor Stented Tissue Valve$165
- SYMPLICITY G3$159
- CDS broad portfolio offering$146
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$144
- HeartMate$143
- COBALT DR MRI SURESCAN$136
How this compares
$38,371 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 536 | $539,921 |
| EntrestoSacubitril/Valsartan | 199 | $185,158 |
| XareltoRivaroxaban | 100 | $108,661 |
| JardianceEmpagliflozin | 133 | $106,837 |
| FarxigaDapagliflozin Propanediol | 120 | $105,583 |
| Repatha SureclickEvolocumab | 128 | $96,969 |
| BrilintaTicagrelor | 49 | $27,210 |
| WegovySemaglutide | 12 | $17,700 |
| OzempicSemaglutide | 15 | $15,009 |
| Atorvastatin Calcium | 1,224 | $12,432 |
| Metoprolol Succinate | 854 | $10,530 |
| Praluent PenAlirocumab | 19 | $9,340 |
| CorlanorIvabradine Hcl | 14 | $8,744 |
| Losartan Potassium | 881 | $6,771 |
| Rosuvastatin Calcium | 396 | $6,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $585 | $539,921536 claims |
| NovartisEntresto | $1,120 | $185,158199 claims |
| AstraZenecaFarxiga, Brilinta | $608 | $132,794169 claims |
| Johnson & JohnsonXarelto | $532 | $108,661100 claims |
| Boehringer IngelheimJardiance | $648 | $106,837133 claims |
| Novo NordiskWegovy, Ozempic | $218 | $32,70927 claims |
| AmgenCorlanor | $775 | $8,74414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Cherry Hill
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.